InsiderClue
← All stocks

Aurinia Pharmaceuticals Inc.

AUPH Net buying
CIK 0001600620 #1941 in the set updated 17 Sep 2026
Bought (120 mo)
$63.16M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$42.41M
$0.00 on a plan · $21.68M straight out of an exercise
Sold at will
$20.73M
61 of 80 sales
Net
+$20.75M
+$42.43M against sales at will

By person

25 insiders · 130 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
TANG KEVIN
Chief Executive Officer
$62.27M (23)
—
+$62.27M
13,044,106
9.80%
$208.05M
+80.4%
Solomons Neil
Chief Medical Officer
—
$13.31M (10) scheduled
−$13.31M
90,953
0.0684%
$1.45M
−51.4%
Martin Michael Robert
Chief Business Officer
$154.80K (1)
$12.85M (19) scheduled
−$12.70M
259,162
0.1948%
$4.13M
−1.9%
Huizinga Robert Bindert
EVP of Research
—
$5.48M (8) scheduled
−$5.48M
69,379
0.0521%
$1.11M
−33.0%
Greenleaf Peter
Chief Executive Officer
$54.89K (2)
$3.98M (5)
−$3.93M
1,840,379
1.38%
$29.35M
+448.8%
Robertson Stephen P.
Chief Legal Officer
$14.53K (1)
$2.02M (6)
−$2.00M
588,848
0.4426%
$9.39M
+413.0%
Miller Joseph M
Chief Financial Officer
$9.74K (1)
$1.27M (5)
−$1.26M
576,421
0.4332%
$9.19M
+396.1%
Donley Matthew Maxwell
Chief Operating Officer
$146.34K (2)
$1.26M (4)
−$1.11M
680,299
0.5113%
$10.85M
+474.2%
Hagan Joseph P
Director
—
$906.53K (3) scheduled
−$906.53K
11,961
0.0090%
$190.78K
+241.7%
Keenan Greg
SVP, Chief Medical Officer
—
$376.26K (3)
−$376.26K
154,449
0.1161%
$2.46M
+38.6%
MILNE GEORGE M JR
Director
$297.38K (3)
—
+$297.38K
78,733
0.0592%
$1.26M
+96.8%
Habig Scott Michael
Chief Commercial Officer
$25.08K (1)
$283.40K (3)
−$258.33K
456,338
0.3430%
$7.28M
+231.8%
Knappertz Volker
EVP, Research and Development
—
$167.87K (2)
−$167.87K
319,128
0.2399%
$5.09M
+102.3%
Jayne David R.W.
Director
—
$126.72K (2)
−$126.72K
56,499
0.0425%
$901.16K
+41.2%
Billen Daniel
Director
—
$82.51K (2)
−$82.51K
28,141
0.0212%
$448.85K
+40.7%
Smith Karen L.
Director
—
$44.18K (1)
−$44.18K
24,807
0.0186%
$395.67K
—
Colao Massimilano
Chief Commercial Officer
—
$38.49K (1)
−$38.49K
13,495
0.0101%
$215.25K
+64.6%
Bailey Jeffrey Allen
Director
—
$38.42K (1)
−$38.42K
22,775
0.0171%
$363.26K
—
MacKay-Dunn R. Hector
Former Director
$105.51K (5)
$86.57K (2)
+$18.95K
18,595
0.0140%
$296.59K
+1,140%
Balakrishnan Brinda
Director
—
$2.98K (1)
−$2.98K
17,523
0.0132%
$279.49K
—
Leversage Jill
Director
$85.10K (4)
$86.42K (2)
−$1.32K
26,453
0.0199%
$421.93K
+2,545%
Hearne Michael S
Chief Financial Officer
—
—
—
116,144
0.0873%
$1.85M
—
Cole Ryan
Chief Operating Officer
—
—
—
116,144
0.0873%
$1.85M
—
Hayden Michael R
Director
—
—
—
95,000
0.0714%
$1.52M
—
Johnson Craig A
Director
—
—
—
14,592
0.0110%
$232.74K
—

Individual transactions

7
Insider
Date
Role
Action
Shares
Price
Amount
Solomons Neil
13 Sep 2021
Chief Medical Officer
Exercised, kept
150,000
$3.20
$480.00K
Martin Michael Robert
13 Sep 2021
Chief Business Officer
Exercised, kept
25,000
$5.30
$132.50K
Huizinga Robert Bindert
11 May 2021
Ex Vice President of Research
Exercised, kept
40,000
$3.02
$120.80K
Martin Michael Robert
11 May 2021
Chief Business Officer
Exercised, kept
20,000
$3.02
$60.40K
Hayden Michael R
29 Jan 2021
Director
Exercised, kept
15,000
$6.42
$96.30K
Hayden Michael R
29 Jan 2021
Director
Exercised, kept
30,000
$6.06
$181.80K
Hayden Michael R
29 Jan 2021
Director
Exercised, kept
50,000
$5.44
$272.00K
Show all 130 transactions →

What was left out

Form 4 filings counted 150
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 19
Sales at will 61
Transactions with no price 0
Shares from compensation/vesting 7,752,523
Sales filed before the plan box existed 27
History held since 29 Jan 2021